These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33296560)

  • 21. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
    Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mortality After Paclitaxel-Coated Device Use in Dialysis Access: A Systematic Review and Meta-Analysis.
    Dinh K; Limmer AM; Paravastu SCV; Thomas SD; Bennett MH; Holden A; Varcoe RL
    J Endovasc Ther; 2019 Oct; 26(5):600-612. PubMed ID: 31455140
    [No Abstract]   [Full Text] [Related]  

  • 24. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
    Brodmann M; Werner M; Meyer DR; Reimer P; Krüger K; Granada JF; Jaff MR; Schroeder H;
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2357-2364. PubMed ID: 30522663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
    Ott I; Cassese S; Groha P; Steppich B; Voll F; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Wittmann T; Kasel AM; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28743787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comments on the current crisis with paclitaxel eluting lower extremity endovascular devices.
    Veith FJ
    J Cardiovasc Surg (Torino); 2019 Aug; 60(4):431-432. PubMed ID: 31165608
    [No Abstract]   [Full Text] [Related]  

  • 30. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
    Zeller T; Langhoff R; Rocha-Singh KJ; Jaff MR; Blessing E; Amann-Vesti B; Krzanowski M; Peeters P; Scheinert D; Torsello G; Sixt S; Tepe G;
    Circ Cardiovasc Interv; 2017 Sep; 10(9):e004848. PubMed ID: 28916599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
    Torsello G; Stavroulakis K; Brodmann M; Micari A; Tepe G; Veroux P; Benko A; Choi D; Vermassen FEG; Jaff MR; Guo J; Dobranszki R; Zeller T;
    J Endovasc Ther; 2020 Oct; 27(5):693-705. PubMed ID: 32583749
    [No Abstract]   [Full Text] [Related]  

  • 33. Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?
    Gad MM; Karrthik AK; Mahmoud AA; Mahmoud AN
    Curr Cardiol Rep; 2019 Sep; 21(10):126. PubMed ID: 31494770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
    Herten M; Torsello GB; Schönefeld E; Stahlhoff S
    Vasc Health Risk Manag; 2016; 12():341-56. PubMed ID: 27621646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
    Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
    Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis.
    Rocha-Singh KJ; Duval S; Jaff MR; Schneider PA; Ansel GM; Lyden SP; Mullin CM; Ioannidis JPA; Misra S; Tzafriri AR; Edelman ER; Granada JF; White CJ; Beckman JA;
    Circulation; 2020 Jun; 141(23):1859-1869. PubMed ID: 32370548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease.
    Mills JL; Conte MS; Murad MH
    J Vasc Surg; 2019 Jul; 70(1):3-7. PubMed ID: 31230649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
    Scheinert D; Schulte KL; Zeller T; Lammer J; Tepe G
    J Endovasc Ther; 2015 Feb; 22(1):14-21. PubMed ID: 25775674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of adjunctive drug-coated balloon therapy in endovascular treatment of common femoral artery disease.
    Imran HM; Hyder ON; Soukas PA
    Cardiovasc Revasc Med; 2019 Mar; 20(3):210-214. PubMed ID: 29970328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.